File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

TitleOutcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases
Authors
Issue Date2003
PublisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2003, v. 52 n. 11, p. 1644-1648 How to Cite?
AbstractINTRODUCTION: Information on treatment outcomes with interferon plus ribavirin combination therapy in chronic hepatitis C patients with normal alanine aminotransaminase (ALT) levels is limited. AIM: The aims of this study were to assess outcomes of treatment with interferon plus ribavirin in patients with normal ALT levels (normal ALT group, n=52) compared with those with elevated ALT levels (raised ALT group, n=53), and to document the rate at which patients with normal ALT levels have an apparent worsening of disease, as shown by increases in ALT levels. RESULTS: At the end of treatment (week 48), 31 patients (59.6%) in the normal ALT group and 30 patients (56.6%) in the raised ALT group had undetectable hepatitis C virus (HCV) RNA (p=0.75). A sustained virological response (SVR) was achieved in 20 patients (38.5%) in the normal ALT group and in 21 patients (39.6%) in the raised ALT group (p=0.90). Patients were subsequently followed up for a median of 29.8 (interquartile range 25th-75th percentile (IQR) 20.8-36.2) months in the normal ALT group and for a median of 26.1 (IQR 17.7-36.3) months in the raised group (p=0.20) after week 72 of treatment. Among patients without SVR in the normal ALT group, only three patients (9.4%) developed persistently raised ALT levels following therapy. CONCLUSIONS: Combination therapy with interferon plus ribavirin is associated with a similar SVR in patients with normal ALT levels compared with those with elevated ALT levels. In patients with normal ALT levels, virological non-response to therapy results in new elevations in serum ALT levels in a small minority only.
Persistent Identifierhttp://hdl.handle.net/10722/44969
ISSN
2015 Impact Factor: 14.921
2015 SCImago Journal Rankings: 6.474
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorMonto, Aen_HK
dc.contributor.authorBelaye, Ten_HK
dc.contributor.authorLau, Een_HK
dc.contributor.authorWright, TLen_HK
dc.date.accessioned2007-10-30T06:14:40Z-
dc.date.available2007-10-30T06:14:40Z-
dc.date.issued2003en_HK
dc.identifier.citationGut, 2003, v. 52 n. 11, p. 1644-1648en_HK
dc.identifier.issn0017-5749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/44969-
dc.description.abstractINTRODUCTION: Information on treatment outcomes with interferon plus ribavirin combination therapy in chronic hepatitis C patients with normal alanine aminotransaminase (ALT) levels is limited. AIM: The aims of this study were to assess outcomes of treatment with interferon plus ribavirin in patients with normal ALT levels (normal ALT group, n=52) compared with those with elevated ALT levels (raised ALT group, n=53), and to document the rate at which patients with normal ALT levels have an apparent worsening of disease, as shown by increases in ALT levels. RESULTS: At the end of treatment (week 48), 31 patients (59.6%) in the normal ALT group and 30 patients (56.6%) in the raised ALT group had undetectable hepatitis C virus (HCV) RNA (p=0.75). A sustained virological response (SVR) was achieved in 20 patients (38.5%) in the normal ALT group and in 21 patients (39.6%) in the raised ALT group (p=0.90). Patients were subsequently followed up for a median of 29.8 (interquartile range 25th-75th percentile (IQR) 20.8-36.2) months in the normal ALT group and for a median of 26.1 (IQR 17.7-36.3) months in the raised group (p=0.20) after week 72 of treatment. Among patients without SVR in the normal ALT group, only three patients (9.4%) developed persistently raised ALT levels following therapy. CONCLUSIONS: Combination therapy with interferon plus ribavirin is associated with a similar SVR in patients with normal ALT levels compared with those with elevated ALT levels. In patients with normal ALT levels, virological non-response to therapy results in new elevations in serum ALT levels in a small minority only.en_HK
dc.format.extent191491 bytes-
dc.format.extent2221 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsGut. Copyright © B M J Publishing Group.en_HK
dc.subject.meshAlanine-Transaminase-blooden_HK
dc.subject.meshAntiviral-Agents-therapeutic-useen_HK
dc.subject.meshHepatitis-C,-Chronic-drug-therapyen_HK
dc.subject.meshInterferon-alpha-therapeutic-useen_HK
dc.subject.meshRibavirin-therapeutic-useen_HK
dc.titleOutcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminasesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0017-5749&volume=52&issue=11&spage=1644&epage=1648&date=2003&atitle=Outcomes+of+interferon+alpha+and+ribavirin+treatment+for+chronic+hepatitis+C+in+patients+with+normal+serum+aminotransaminasesen_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/gut.52.11.1644-
dc.identifier.pmid14570736-
dc.identifier.pmcidPMC1773858-
dc.identifier.scopuseid_2-s2.0-0242298192-
dc.identifier.isiWOS:000186070800020-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats